EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Aug-17-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Jul-16-26 | Initiated | Stifel | Buy | $40 |
| Jul-08-26 | Resumed | Cantor Fitzgerald | Overweight | $47 |
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform | $28 |
| Jan-07-25 | Initiated | Citigroup | Buy | $33 |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform | |
| Aug-28-24 | Initiated | Jefferies | Buy | $15 |
| Jan-22-24 | Initiated | JP Morgan | Overweight | $35 |
| Nov-02-23 | Initiated | Mizuho | Buy | $20 |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform | $33 |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy | $21 |
| Mar-01-21 | Initiated | Cowen | Outperform | $25 |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight | $22 |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral | $4 → $1 |
| Nov-04-19 | Resumed | Laidlaw | Buy | $5 |
| Sep-12-19 | Initiated | Guggenheim | Buy |